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Background: Treatment of superficial venous reflux in addition to compression therapy 
accelerates venous leg ulcer healing and reduces ulcer recurrence. The aim of this study was 
to evaluate the costs and cost-effectiveness of early versus delayed endovenous treatment of 
patients with venous leg ulcers. 
Methods: This was a within-trial cost-utility analysis with a 1-year time horizon using data 
from the EVRA (Early Venous Reflux Ablation) trial. The study compared early versus 
deferred endovenous ablation for superficial venous truncal reflux in patients with a venous 
leg ulcer. The outcome measure was the cost per quality-adjusted life-year (QALY) over 
1 year. Sensitivity analyses were conducted with alternative methods of handling missing 
data, alternative preference weights for health-related quality of life, and per protocol. 
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Results: After early intervention, the mean(SE) cost was higher (difference in cost per patient 
£163(SE 318; €184, SE 358)) and early intervention was associated with more QALYs at 
1 year (mean(SE) difference 0.041(0.017). The incremental cost-effectiveness ratio (ICER) 
was £3976 (€4482) per QALY. There was an 89 per cent probability that early venous 
intervention is cost-effective at a threshold of £20 000 (€22 546)/QALY. Sensitivity analyses 
produced similar results, confirming that early treatment of superficial reflux is highly likely 
to be cost-effective. 
Conclusion: Early treatment of superficial reflux is highly likely to be cost-effective in 
patients with venous leg ulcers over 1 year. Further studies are required to assess the impact 
in the long term. Registration number: ISRCTN02335796 (http://www.isrctn.com).  
 
+A: Introduction 
Leg ulcers are a major burden to healthcare providers and represent a source of discomfort 
and social isolation to patients. In 70 per cent of cases, the underlying cause of leg ulceration 
is venous disease, sometimes evident as varicose veins but often undetectable by visual 
examination alone. One UK study
1
 found a point prevalence of 1.5 cases of complex wounds 
per 1000 population, of which 28 per cent were leg ulcers. It should also be noted that, with 
an ageing and increasingly obese population, the incidence and prevalence of venous 
ulceration are both likely to increase. Treatment of venous leg ulcers has been estimated to 
cost £941 (€1061) million per annum in the UK2. 
Venous leg ulcers are characterized by protracted healing. Some patients may never 
heal, and those who do are at high risk of recurrence
3
. The mainstay of therapy for venous 
ulceration is compression therapy using bandages or stockings
3
. Current guidelines
4
 
recommend treatment of superficial venous reflux using endovenous ablation techniques 
(ultrasound-guided foam sclerotherapy (UGFS), endovenous laser or radiofrequency 
ablation), but many practitioners delay intervention until the ulcer has healed. More recently, 
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the EVRA trial
5
 found that early endovenous ablation significantly reduced time to ulcer 
healing. This study presents an analysis of the cost-effectiveness of early versus delayed 
endovenous treatment, based on the EVRA trial data to 1 year. The protocol is available at 
http://www.imperial.ac.uk/media/imperial-college/medicine/surgery-cancer/clinical-
trials/EVRA-Protocol-06.04.2017.pdf. 
+A: Methods 
This study was a within-trial cost-utility analysis comparing early versus deferred 
endovenous ablation for truncal superficial venous reflux in patients with venous ulceration, 
within a 1-year time horizon. The primary difference between the two strategies was the 
timing of endovenous ablation: patients in the early intervention arm were treated within 
2 weeks of randomization, whereas those randomized to deferred intervention arm underwent 
endovenous ablation once the ulcer had healed, or after 6 months. All patients were treated 
with compression therapy in accordance with local standard practice. 
Patients in the EVRA trial were aged at least 18 years, presented with a venous leg 
ulcer of between 6 weeks’ and 6 months’ duration, ankle : brachial pressure index 0.8 or 
above, able to tolerate compression therapy, and had superficial venous reflux requiring 
endovenous ablation. Patients were recruited from 20 vascular centres in the UK, and 
endovenous interventions were performed in outpatient clinic, operating room or treatment 
room settings (as per local practice). Most leg ulcer management takes place in a community 
care setting (community clinics or patient’s home) or in primary care clinics. 
+B: Outcome assessment 
The cost analyses were performed from the perspective of the UK National Health Service 
and Personal Social Services in accordance with UK methods guidance
6
. The price year was 
2015–2016, and currency conversion was calculated at 2016 purchasing power parity7. No 
discounting was applied as the follow-up was 1 year. The study was reported according to 
guidelines for economic evaluation
8
.  
The primary health outcome in the cost-effectiveness analysis was QALYs at 
1 year. Participants in the EVRA study were asked to complete the EQ-5D-5L™ (EuroQol 
Group, Rotterdam, the Netherlands) questionnaire at baseline, 6 weeks, 6 months and 1 year 
after randomization. EQ-5D™ is an instrument to measure generic health-related quality of 
life and has been validated in this population
9
. To convert patient responses into a health 
utility scale (where 1 represents perfect health and 0 a state equivalent to death), the base-
case economic analysis used the crosswalk tariff, as recommended by the UK National 
Institute for Health and Care Excellence (NICE) in August 2017
10
. This algorithm maps the 
EQ-5D™ five-level responses to three-level responses, and then values those health states 
using the original EQ-5D™ three-level tariff developed by Dolan
11
. As a sensitivity analysis, 
an alternative health utility tariff developed by Devlin and colleagues
12
 for the EQ-5D-5L™ 
was used. Quality-adjusted life-years (QALYs) were estimated for each participant to 1 year 
as the area under the curve of EQ-5D-5L™ index values. 
Resource use items were recorded for each participant at monthly follow-up telephone 
calls. The total cost per patient included the following resource items for vein or ulcer-related 
reasons: trial endovenous ablation procedures, dressings and bandaging consumables for 
wound healing, compression therapy to prevent recurrence after wound healing, visits to or 
from a district nurse, visits to or from a general practitioner, visits to a primary care practice 
nurse, inpatient and day-case hospital admissions, outpatient visits, use of antiplatelet and 
anticoagulant medicines, physiotherapy and occupational therapy, auxiliary nursing (home 
care) and personal care (home help). 
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To obtain a precise estimate of the effect of the intervention on healthcare use, and 
avoid statistical noise, the study aimed to include only resource use related to the ulcer. 
Researchers recorded the reason for the use of each item of healthcare as free text. Ulcer-
related activity was considered to include: ulcer care, skin care, leg care, venous procedures, 
angiography, infection, rehabilitation, deep vein thrombosis and related keywords. Non-
ulcer-related healthcare, as well as out-of-pocket expenses and time lost from usual activities, 
were tabulated but not included in total cost per patient. Costs were estimated by multiplying 
resource use by unit costs obtained from published literature
13
, national unit cost databases 
for the UK
14–18
, and manufacturers’ list prices for catheters and other disposable items 
(Table S1, supporting information). Currency conversions (£GBP/€EURO) were calculated to 
the rate applicable at the time of conversion (£1 = €1.1273; 20 September 2018). 
+B: Handling of missing data 
There was a small amount of missing data in the trial owing to patient withdrawal and other 
reasons. Costs and EQ-5D-5L™ index were set to zero after the date of death. The base-case 
cost-effectiveness analysis used complete cases in an intention-to-treat analysis. A participant 
was considered a complete case if they completed all the EQ-5D™ questions at baseline, 
6 weeks, 6 months and 1 year, and did not withdraw from the study before 12 months. 
As a sensitivity analysis, multiple imputation using chained equations was employed to 
impute the remaining missing data by regression under the assumption of ‘missingness at 
random’ (Appendix S1, supporting information)19. Missing costs in each treatment group 
were considered predictable from observed data, plus or minus a random error. For those lost 
to follow-up, costs for each participant were imputed at each month after the time of 
withdrawal, and the EQ-5D-5L™ index was imputed at 6 weeks, 6 months and 1 year if these 
data were missing. Ten imputed data sets were created and analysed using Rubin’s rules (this 
was sufficient to give stable results allowing for Monte Carlo error)
19
. 
+B: Handling of protocol deviations 
In the clinical study, protocol deviations were seen in 117 patients (59 and 58 in early and 
deferred groups respectively), the majority of which were late or missed follow-up 
appointments (40 of 59 patients in the early intervention group and 34 of 58 in the deferred 
intervention group)
5
. A sensitivity analysis was carried out excluding these patients. 
+B: Cost-effectiveness analysis 
The difference in mean total cost and mean total QALY per participant between the treatment 
groups was estimated using regression methods, including baseline EQ-5D-5L™ in the 
QALY regression Monte Carlo resamples
20
. 
The incremental cost-effectiveness ratio (ICER) was calculated. An intervention may 
be considered cost-effective when its ICER is less than the threshold set by health policy 
decision-makers
21
. In the UK, the cost-effectiveness threshold is in the range £20 000 - £30 
000 (€22 546 - €33819)/per QALY6.  
The probability that early ablation was more cost-effective than deferred ablation was 
estimated at different cost-effectiveness thresholds. The base-case analysis used 
bootstrapping, with 1000 Monte Carlo resamples with replacement. The bootstrap was used 
only for the analysis of complete cases, as bootstrap combined with multiple imputation can 
be very complex
22
. As an alternative method in sensitivity analyses, standard errors and 
correlation between total costs and QALYs were estimated assuming bivariable normality 
(Appendix S1, supporting information). 
+B: Sensitivity analyses 
Five models were estimated: model 1, the base case – complete cases with bootstrap standard 
errors and crosswalk EQ-5D-5L™ tariff; model 2, complete case with bivariable normal 
standard errors and crosswalk EQ-5D-5L™ tariff; model 3, multiple imputation with 
Deleted: £20 000 
bivariable normal standard errors and crosswalk EQ-5D-5L™ tariff; model 4, complete case 
with bootstrap standard errors and EQ-5D-5L™ tariff estimated according to Devlin et al.12; 
model 5, per-protocol analysis (this was the same as model 1, but excluded patients with a 
protocol deviation). 
+A: Results 
Baseline characteristics for the study groups, described in full elsewhere
5
, were evenly 
matched across the arms of the EVRA trial (Table 1). 
+B: Resource use and total cost analysis 
The total mean cost per patient over 1 year, excluding patients who did not complete follow-
up to 12 months are shown in Table S2 (supporting information). Participants who died 
during the year were included in these data, with costs set to zero after the date of death. For 
the purposes of this analysis, 419 patients completed 12 months of the study or died, 211 in 
the deferred ablation group (226 randomized, less 15 withdrawals or lost to follow-up) versus 
208 in the early group (224 randomized, less 16 withdrawals or lost to follow-up). 
The total mean (SD) cost per patient over 1 year was similar in the two study groups: 
£2514 (SD 2770; €2834, SD 3123) for 208 patients randomized to early ablation versus 
£2516 (SD 3242; €2836, SD 3655) for 211 patients in the deferred group (Fig.1). 
The early ablation group incurred a greater initial cost due to the allocated endovenous 
ablation procedure. Although the study protocol recommended that participants in the 
deferred group should have an ablation procedure once the ulcer had healed, many did not 
receive this treatment. At 1 year, 55 of the 226 patients in the deferred arm had received no 
intervention, compared with seven of 224 in the early arm (Table S2, supporting 
information). Of the 55 with no intervention in the deferred arm, 35 subjects completed the 
study, of whom 26 had a healed ulcer after 1 year. Reasons for not performing ablation 
Deleted: s.d.
procedures in participants randomized to deferred ablation were unclear, but both participant 
and clinician preferences are likely to have played a role. The greater initial costs in the early 
ablation group were compensated by lower costs of district nurse home visits due to quicker 
wound healing (Table S2, supporting information). Other resource use was similar in the two 
groups. 
+B: Cost-effectiveness analysis 
Table 2 shows the results of the cost and QALY regressions for the cost-effectiveness 
analyses. In the complete case analysis (model 1 or base case), 106 of 450 patients (23.6 per 
cent) had incomplete EQ-5D™ or cost data over the year, and thus 344 (76.4 per cent) were 
included in this analysis. The proportion of missing data was similar in early (22.8 per cent) 
and deferred (24.3 per cent) intervention arms. Greater costs and QALYs were recorded for 
patients in the early intervention group, with a mean (SE) difference in cost per patient of 
£163(SE 318; €184, SE 358), a difference in QALYs at 1 year of 0.041(0.017). The ICER 
was £3976(€4482)/QALY. There was an 89 per cent probability that early endovenous 
intervention is cost-effective at a threshold of £20 000(€22 546)/QALY (Fig. 2). When 
bivariable normality was assumed to estimate standard errors, the results were similar (model 
2). There was a significant negative correlation between costs and QALYs, indicating that 
participants with a worse quality of life were also those who tended to incur greater 
healthcare costs (correlation –0.294, P < 0.001). 
In model 3, missing data were imputed. All 450 randomized patients were included in 
this model. The mean(SE) difference in total cost was −£72(SE 290; -€81, SE 327) (early 
intervention was cost-saving) and the mean difference in QALYs over 1 year was 
0.058(0.018) (greater in the early intervention group), with a greater than 99 per cent 
probability of being cost-effective at a threshold of £20 000(€22 546)/QALY. The use of 
alternative tariff values for the EQ-5D-5L™ (model 4) resulted in a slightly smaller 
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difference in QALYs between the treatment groups than for the base case, but the ICER was 
similar. 
The per-protocol analysis was carried out using the same approach as model 1, but 
excluding patients with protocol deviations. Protocol deviations were seen in 117 patients (59 
and 58 in early and deferred groups respectively), of whom 71 had complete data. This left 
273 patients for analysis (344 with complete data at 12 months, less 71 protocol deviations). 
The ICER was £8679 (€9784)/QALY (model 5). 
+A: Discussion 
This study has demonstrated that early endovenous intervention for superficial venous reflux 
is highly likely to be a cost-effective treatment for patients with a venous leg ulcer. The 
complete case analysis showed little difference in total mean cost per patient over 1 year 
between the early and deferred ablation strategies (mean(SE) difference £163(SE 318; €184, 
SE 358), P = 0.607). The greater initial mean cost of the early intervention strategy was 
mostly offset by the reduced cost of treating unhealed leg ulcers. There was, however, a 
substantial and statistically significant gain in QALYs over 1 year, with a mean difference of 
0.041(0.017) in favour of early intervention (P = 0.017). The ICER for early intervention at 
one year is therefore £3976 (€4482)/ QALY.  
From the complete case analysis, the probability of cost-effectiveness was 89 per cent 
using UK thresholds. Therefore, there is little chance that delayed ablation would offer 
greater net benefit at conventional thresholds of willingness-to-pay. Sensitivity analyses 
using alternative statistical models gave qualitatively similar results. 
This economic analysis compared early versus delayed endovenous ablation for venous 
leg ulcers. Tricco and colleagues
23
 reviewed studies that evaluated the costs and benefits of 
alternative medical therapeutic strategies. [1][2] It was notable that the difference in QALYs 
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between the strategies reported by these studies was generally small. For example, the largest 
QALY gain observed in any previous study was in VenUS I (difference of 0.02 QALYs for 
four-layer bandages versus short stretch bandages)
24
. The difference in QALYs between early 
and delayed ablation found in the present study was much larger: 0.041 over 1 year. This 
study did not consider whether cost-effectiveness might vary across subgroups. The EVRA 
trial
5
 assessed the clinical benefit across several predefined subgroups and detected some 
interesting trends for potentially greater benefits for early intervention, such as in patients 
with longer ulcer duration. However, the clinical study was not powered to detect differences 
across subgroups, and furthermore patients with ulcer duration more than 6 months were 
excluded. Thus, further studies are required to confirm these findings and assess whether 
there may be greater cost-effectiveness in these populations, or with specific endovenous 
interventions such as UGFS. 
The benefits of early endovenous ablation in the present study arose because of faster 
ulcer healing in the first 12 months after randomization. The long-term benefits and costs will 
also depend on whether the treatments can reduce ulcer recurrence rates. Evidence from other 
randomized trials suggests that surgical intervention for superficial reflux reduces recurrence, 
compared with compression therapy alone
25
. If early endovenous ablation can impact on both 
healing and recurrence, it could be even more cost-effective over the patient’s lifetime26. In 
the EVRA study, there were insufficient recurrences over 1 year to permit meaningful 
comparison. Evaluation of ulcer recurrence in the EVRA population is ongoing. 
This study showed that early endovenous ablation had a significant and substantial 
impact on a patient’s quality of life, with no material increase in the burden of cost on payers. 
Hence this strategy is very likely to be cost-effective. The resources needed for 
implementation of an early intervention strategy will depend on the individual setting
3
, but 
any effective wound management strategy would require close multidisciplinary teamwork 
between primary care and specialist vascular centres, in order to conduct prompt assessment 
of promptly assess patients with a venous leg ulcer, referral and treatment of superficial 
venous reflux. 
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<TYPESETTER: PLEASE FOLLOW MARK-UPS OF FIGS 1 & 2> 
Fig. 1 Costs of early and deferred strategies for treatment of venous leg ulcers over 
1 year 
Mean National Health Service and personal social services costs for early versus deferred 
strategies for patients with complete data on costs.  
 
Fig. 2 Cost-effectiveness acceptability curves for models 1–5 
Model 1, complete case; model 2, complete case using bivariable normal model; model 3, 
multiple imputation; model 4, alternative EQ-5D-5L™ tariff; model 5, per-protocol. QALY, 
quality-adjusted life-year, 
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 Table 1 Baseline characteristics of trial participants 
 Early 
intervention 
(n = 224) 
Deferred 
intervention 
(n = 226) 
Total 
(n = 450) 
Age (years)* 67.0(15.5) 68.9(14.0) 68.0(14.8) 
Height (cm)* 171.9(11.1) 170.5(10.8) 171.2(11.0) 
Weight (kg)* 89.5(25.6) 88.8(24.1) 89.1(24.9) 
BMI (kg/m
2
)* 30.1(7.8) 30.4(7.4) 30.3(7.6) 
Sex    
F 97 (43.3) 106 (46.9) 203 (45.1) 
M 127 (56.7) 120 (53.1) 247 (54.9) 
Smoking    
Current 23 (10.3) 19 (8.4) 42 (9.3) 
Former 86 (38.4) 101 (44.7) 187 (41.6) 
Never 115 (51.3) 106 (46.9) 221 (49.1) 
Ethnicity    
White 206 (92.0) 208 (92.0) 414 (92.0) 
Mixed 1 (0.4) 0 (0) 1 (0.2) 
Asian 11 (4.9) 12 (5.3) 23 (5.1) 
Black 3 (1.3) 5 (2.2) 8 (1.8) 
Other 3 (1.3) 1 (0.4) 4 (0.9) 
EQ-5D™    
Health state score 70.2(17.7) 70.1(17.1) 70.2(17.4) 
Index value 0.7(0.2) 0.7(0.2) 0.7(0.2) 
SF-36*    
Physical function 37.3(12.0) 37.5(12.5) 37.4(12.2) 
Role physical 39.0(12.2) 39.7(12.1) 39.4(12.2) 
Body pain 41.3(11.1) 41.6(11.9) 41.4(11.5) 
General health 45.8(9.2) 46.0(9.8) 45.8(9.5) 
Vitality 48.2(10.2) 47.8(10.6) 48.0(10.4) 
Social functioning 42.6(12.4) 42.4(13.5) 42.5(13.0) 
Role emotional 42.7(13.8) 43.7(13.6) 43.2(13.7) 
Mental health 49.2(10.3) 49.3(10.7) 49.2(10.5) 
Physical component summary 38.5(9.9) 38.8(10.8) 38.6(10.4) 
Mental component summary 49.2(10.9) 49.4(11.6) 49.3(11.2) 
Total AVVQ*  44.1(9.0) 44.3(8.7) 44.2(8.8) 
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). 
Data for up to seven patients were missing for some continuous variables. SF-36, Short Form 
36; AVVQ, ???. Adapted from Gohel MS, Heatley F, Liu X, Bradbury A, Bulbulia R, Cullum 
N et al.; EVRA Trial Investigators. A randomized trial of early endovenous ablation in 
venous ulceration. N Engl J Med 2018; 378: 2015–2114. Copyright © (2018) Massachusetts 
Medical Society. 
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Table 2 Results of regression for cost-effectiveness analysis 
 
Model 1* Model 2† Model 3† Model 4 Model 5 
Coefficient Complete case 
(n = 344), with 
bootstrap 
standard errors 
(1000 samples) 
and crosswalk 
EQ-5D™ tariff 
Complete case 
(n = 344), with 
bivariable 
normal 
standard errors 
and crosswalk 
EQ-5D™ tariff 
10 multiple 
imputations 
(n = 450), with 
bivariable 
normal standard 
errors and 
crosswalk EQ-
5D™ tariff 
Complete case 
(n = 344) with 
bootstrap 
standard errors 
and Devlin 
EQ-5D-5L™ 
tariff 
Per-protocol 
compliers 
(n = 273) 
with 
bootstrap 
standard 
errors 
Difference 
in cost  
     
Mean(s.e.) £163(318) 
(€184(358)) 
£163(322) 
(€184(363)) 
−£72(290) 
(-€81(327)) 
£163(322) 
(€184(363)) 
£486(326) 
(€548(367)) 
P 0.607 0.612 0.803 0.612 0.137 
Difference 
in QALYs 
     
Mean(s.e.) 0.041(0.017) 0.041(0.018) 0.058(0.018) 0.033(0.016) 0.056(0.019) 
P 0.017 0.024 0.002 0.039 0.003 
ICER 
(£/QALY) 
3976 
(€4482) 
3976 
(€4482) 
n.c. 4939 
(€5568) 
8679 
(€9784) 
*Base-case or primary analysis. †Estimated correlation of residuals between cost and quality-adjusted life-years 
(QALYs) in the bivariable normal model: −0.294 (P < 0.001). n.c., Incremental cost-effectiveness ratio (ICER) 
not calculable because early ablation dominates (both cost-saving and more effective). Currency conversions 
(£GBP/€EURO) are correct at the date of conversion (£1 = €1.1273; 20 September 2018). 
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